Last edition
News about "chronic kidney disease "
Chugai Files Regulatory Application in Japan for IgA Nephropathy Drug Sparsentan
Chugai Pharmaceutical has applied for regulatory approval in Japan for sparsentan, a dual-action oral therapy for IgA nephropathy. Clinical studies showed significant reductions in proteinuria and potential benefits in preserving kidney function, offering hope for patients with limited treatment options.
Chronic Kidney Disease | 20/06/2026 | By News Bureau | 130
AstraZeneca Pharma India has launched K+ Connect, a nationwide initiative bringing together multidisciplinary experts from 33 healthcare centres to strengthen long-term hyperkalaemia management in patients with heart failure and chronic kidney disease.
Chronic Kidney Disease | 14/05/2026 | By News Bureau
Alebund Pharmaceuticals has completed patient enrollment in its global phase 3 RESPOND-2 study evaluating AP301, a next-generation phosphate binder for CKD patients on dialysis.
Chronic Kidney Disease | 07/05/2026 | By News Bureau | 132
Mankind Pharma Urges Greater Kidney Health Awareness as CKD Burden Rises
On World Kidney Day, Mankind Pharma highlights rising cases of Chronic Kidney Disease in India and stresses early screening, lifestyle changes and awareness to prevent late-stage diagnosis.
Chronic Kidney Disease | 12/03/2026 | By News Bureau | 145
TaiGen Biotechnology doses first participant in Phase I trial of ISM4808, an AI-designed oral therapy from Insilico Medicine for chronic kidney disease-related anemia.
Chronic Kidney Disease | 09/03/2026 | By News Bureau | 226
Amphastar Secures FDA Approval for Generic Iron Sucrose Injection
The US FDA has approved Amphastar's Abbreviated New Drug Application (ANDA) for iron sucrose injection, an iron replacement product indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease.
Chronic Kidney Disease | 12/08/2025 | By Dineshwori | 328
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy